- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03273257
Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)
A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multicentre, Prospective Study to Assess Efficacy of Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy With High Preoperative Pulmonary Vascular Resistance
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Paris, France
- Hopital de Bicetre
-
-
-
-
-
Bad Nauheim, Germany, 61231
- Kerckhoff-Klinik GmbH
-
-
-
-
-
Cambridge, United Kingdom, CB3 8RE
- Papworth Hospital
-
-
-
-
California
-
La Jolla, California, United States, 92037-7892
- UC San Diego
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Is a male or nonpregnant and nonlactating female patient aged from 18 to 80 years, both inclusive
- Is diagnosed with operable CTEPH and anticipating symptomatic and/or prognostic benefit from PEA
- Has pulmonary vascular resistance (PVR) >800 dyn·s·cm-5
- Has undergone right heart catheterisation not more than 180 days before randomisation visit
- Has been treated with anticoagulants for at least 90 days before randomisation visit
- Has ability to swallow oral medication
- Has ability and willingness to participate and access the health facility
- Is capable of understanding the written informed consent and provides signed and witnessed written informed consent
- Female patient must be either surgically sterile, postmenopausal (no menses for the previous 12 months), or must be practicing an effective method of birth control as determined by the investigator (eg, oral contraceptives, double barrier methods, hormonal injectable or implanted contraceptives, tubal ligation, or male partner with vasectomy or complete abstinence)
Exclusion Criteria:
- Has unstable disease in need of urgent PEA surgery as determined by the treating physician
- Has known hypersensitivity, allergic, or adverse reactions to riociguat or any of the excipients comprising riociguat tablets.
- Has known active hepatitis A IgM (HAV-IgM), hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCV Ab)
- Is human immunodeficiency virus positive
- Has pulmonary veno-occlusive disease
- Has symptomatic hypotension
- Has symptomatic carotid disease
- Has significant coronary atherosclerotic disease in need of intervention
- Has severe left heart disease in need of intervention
- Has redo sternotomy
- Has received any background therapy for pulmonary arterial hypertension (PAH) in the preceding 30 days before randomisation visit including endothelin receptor antagonists (ERAs), phosphodiesterase 5 (PDE5) inhibitors, or prostanoids
- Is receiving nitrates, nitric oxide donors (e.g. amyl nitrite), ERAs, prostanoids, specific PDE5 inhibitors, nonspecific phosphodiesterase inhibitors (e.g. dipyridamole, theophylline)
- Is receiving strong cytochrome P450 (CYP) and P-glycoprotein/breast cancer resistance protein inhibitors
- Is receiving strong CYP3A inducers
- Has creatinine clearance <15 mL/min or on any form of dialysis
- Has severe hepatic impairment classified as Child-Pugh C
- Has received an investigational drug within the past 4 weeks before randomisation visit
- Is a lactating or pregnant (as demonstrated by a serum pregnancy test) woman, and not willing to take measures for not to become pregnant during the 3 months treatment study period and one month after the last dose of study drug administered
- Has smoked or used tobacco in any form, including snuff or chewing within 3 months prior to randomisation visit
- Has idiopathic interstitial pneumonitis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Riociguat
Patients will receive riociguat for 3 months followed by pulmonary endarterectomy.
|
Riociguat will be initiated at 1 mg tid. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid. Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability.
Other Names:
PEA will be performed at the end of medical treatment (Day 90)
Other Names:
|
Placebo Comparator: Placebo
Patients will receive placebo for 3 months followed by pulmonary endarterectomy.
|
PEA will be performed at the end of medical treatment (Day 90)
Other Names:
Placebo will be given analogue to riociguat with matching tablets.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Pulmonary Vascular Resistance (PVR) to Immediately Before Pulmonary Endarterectomy (Pre-PEA)
Time Frame: 90 days
|
Pulmonary vascular resistance (PVR) will be assessed at baseline and immediately before pulmonary endarterectomy.
The change in PVR will be assessed as percentage.
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Pulmonary Vascular Resistance (PVR) to 6 Months Post Pulmonary Endarterectomy (PEA)
Time Frame: 270 days
|
Pulmonary vascular resistance (PVR) will be assessed at baseline and 6 months post pulmonary endarterectomy (PEA).
The change in PVR will be assessed as percentage.
|
270 days
|
Number of Patients With Either All-cause Death, PH-related Hospitalization, Need for PAH-targeted Therapy or WHO Functional Class Unchanged or Worse Between Randomization and 6 Months Post Pulmonary Endarterectomy (Composite Endpoint)
Time Frame: 270 days
|
All deaths occurring post-randomization until the last visit will be included. All PH-related hospitalizations except the in-hospital care during and after pulmonary endarterectomy (PEA) from randomization until 6 months after PEA will be included. The worst value for World Health Organization (WHO) functional class after treatment will be used. |
270 days
|
Intraoperative Circulatory Arrest Time
Time Frame: intraoperative
|
Circulatory arrest time will be measured in minutes
|
intraoperative
|
Number of Patients With Intraoperative Surgery-related Complications (Composite Endpoint)
Time Frame: intraoperative
|
The occurrence of any of the following complications will be assessed:
|
intraoperative
|
Surgical Evaluation of Specimen: Stratification of Patients According to Ease of Dissection Plane
Time Frame: intraoperative
|
Classed as easier than normal (1); normal (2); more difficult than normal (3)
|
intraoperative
|
Surgical Evaluation of Specimen: Stratification of Patients According to Completeness of Disease Clearance
Time Frame: intraoperative
|
Classed as better than expected (1); as expected (2); worse than expected (3)
|
intraoperative
|
Surgical Evaluation of Specimen: Stratification of Patients According to Appearance of Clot and Vessel Wall
Time Frame: intraoperative
|
Classed as more solid than usual (1); normal (2); more friable than usual (3)
|
intraoperative
|
Number of Patients Who Died During the Course of the Study
Time Frame: 270 days
|
All deaths occurring during the whole course of the study
|
270 days
|
Patients Who Withdraw During the Randomized Treatment Phase
Time Frame: 90 days
|
Only withdrawals after randomization but before PEA will be included
|
90 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in NT-proBNP From Baseline Until the End of Medical Treatment
Time Frame: 90 days
|
Data are not reported for this exploratory endpoint because of limited sample size due to early termination of the study
|
90 days
|
Change in NT-proBNP From Baseline Until 6 Months Post-surgery
Time Frame: 270 days
|
Data are not reported for this exploratory endpoint because of limited sample size due to early termination of the study
|
270 days
|
Change in Cardiac Index From Baseline Until the End of Medical Treatment
Time Frame: 90 days
|
Data are not reported for this exploratory endpoint because of limited sample size due to early termination of the study
|
90 days
|
Change in Cardiac Index From Baseline Until 6 Months Post-surgery
Time Frame: 270 days
|
Data are not reported for this exploratory endpoint because of limited sample size due to early termination of the study
|
270 days
|
Change in Mean Right Atrial Pressure From Baseline Until the End of Medical Treatment
Time Frame: 90 days
|
Data are not reported for this exploratory endpoint because of limited sample size due to early termination of the study
|
90 days
|
Change in Mean Right Atrial Pressure From Baseline Until 6 Months Post-surgery
Time Frame: 270 days
|
Data are not reported for this exploratory endpoint because of limited sample size due to early termination of the study
|
270 days
|
Change in Mean Pulmonary Atrial Pressure From Baseline Until the End of Medical Treatment
Time Frame: 90 days
|
Data are not reported for this exploratory endpoint because of limited sample size due to early termination of the study
|
90 days
|
Change in Mean Pulmonary Atrial Pressure From Baseline Until 6 Months Post-surgery
Time Frame: 270 days
|
Data are not reported for this exploratory endpoint because of limited sample size due to early termination of the study
|
270 days
|
Change in Pulmonary Artery Wedge Pressure From Baseline Until the End of Medical Treatment
Time Frame: 90 days
|
Data are not reported for this exploratory endpoint because of limited sample size due to early termination of the study
|
90 days
|
Change in Pulmonary Artery Wedge Pressure From Baseline Until 6 Months Post-surgery
Time Frame: 270 days
|
Data are not reported for this exploratory endpoint because of limited sample size due to early termination of the study
|
270 days
|
Length of Hospital Stay for Pulmonary Endarterectomy
Time Frame: intraoperative
|
Data are not reported for this exploratory endpoint because of limited sample size due to early termination of the study
|
intraoperative
|
Length of Intensive Care Unit Stay for Pulmonary Endarterectomy
Time Frame: intraoperative
|
Data are not reported for this exploratory endpoint because of limited sample size due to early termination of the study
|
intraoperative
|
WHO Functional Class at the End of Medical Treatment
Time Frame: 90 days
|
Data are not reported for this exploratory endpoint because of limited sample size due to early termination of the study
|
90 days
|
WHO Functional Class 6 Months Post Pulmonary Endarterectomy
Time Frame: 270 days
|
Data are not reported for this exploratory endpoint because of limited sample size due to early termination of the study
|
270 days
|
Need for PAH-targeted Therapy 6 Months Post-surgery
Time Frame: 270 days
|
Data are not reported for this exploratory endpoint because of limited sample size due to early termination of the study
|
270 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David Jenkins, MD, Papworth Hospital NHS Foundation Trust, Cambridge, UK
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PEA Bridging Study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Thromboembolic Pulmonary Hypertension
-
University of California, San FranciscoRecruitingChronic Thromboembolic Pulmonary Hypertension | Chronic Thromboembolic DiseaseUnited States
-
University of ZurichCompletedPulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension | Chronic Cardiorespiratory DiseaseSwitzerland
-
SciPharm SàRLCompletedNon-operable Chronic Thromboembolic Pulmonary HypertensionAustria, Poland, Czechia, Germany
-
ActelionEPS Corporation; Imepro Inc.; General Laboratory, BML, Inc.; Mitsubishi Logistics...TerminatedChronic Thromboembolic Pulmonary Hypertension (CTEPH)Japan
-
University of California, San DiegoE Squared Trials and Registries, Inc.CompletedPulmonary Hypertension | Chronic Thromboembolic Pulmonary Hypertension (CTEPH)United States
-
Assistance Publique - Hôpitaux de ParisMerck Sharp & Dohme LLCCompletedPulmonary Embolism | Chronic Thromboembolic Pulmonary Hypertension (CTEPH)France
-
University of ZurichCompletedPulmonary Arterial and Chronic Thromboembolic Pulmonary HypertensionSwitzerland
-
University of SheffieldSheffield Teaching Hospitals NHS Foundation TrustUnknownChronic Thromboembolic Pulmonary Hypertension
-
University of AarhusHospitalsenheden VestUnknownChronic Thromboembolic Pulmonary Disease
-
China-Japan Friendship HospitalRecruitingChronic Thromboembolic Pulmonary HypertensionChina
Clinical Trials on Riociguat
-
BayerCompletedPulmonary Disease, Chronic Obstructive | Hypertension, PulmonaryGermany
-
BayerRecruitingHypertension, PulmonaryFrance, Italy, Korea, Republic of, Poland, Thailand
-
BayerXcenda, LLCActive, not recruitingPulmonary Arterial HypertensionUnited States, Puerto Rico
-
BayerCompleted
-
BayerCompletedHypertension, PulmonaryBelgium, United States, Switzerland, Canada, France, Germany, Italy, United Kingdom, Czechia
-
BayerCompletedHypertension, PulmonaryJapan, Germany, Sweden, Colombia, Turkey, Belgium, Canada
-
BayerCompletedHypertension, PulmonaryBelgium, France, China, Turkey, Portugal, Taiwan, Japan, Singapore, United States, Argentina, Switzerland, Mexico, Austria, Thailand, Canada, Denmark, Germany, Russian Federation, Australia, Italy, Korea, Republic of, Sweden, Poland, United... and more
-
BayerCompletedHypertension, PulmonaryTurkey, Austria, Czechia, Russian Federation, Slovakia, Switzerland, Italy, Germany, United Kingdom, France, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Taiwan, Denmark, Sweden, Argentina, Portugal, Saudi Arabia, Austral... and more
-
BayerTerminatedHypertension, Pulmonary | Ventricular Dysfunction, LeftAustria, Germany, Czech Republic